Drug Interaction:
Fluoroquinolones include the following : Ciprofloxacin, Norfloxacin, Lomefloxacin, Ofloxacin, Pefloxacin, Enoxacin
Refer Ciprofloxacin
Antacids containing magnesium and aluminium reduce absorption. Sucralfate reduces absorption. Inhibits GABA receptor binding.
Probenecid decreases elimination.
Indication:
Fluoroquinolones include the following :
Ciprofloxacin, Norfloxacin, Lomefloxacin, Ofloxacin, Pefloxacin, Enoxacin Refer Ciprofloxacin
Approved by FDA in 1990
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
1.Ofloxacin Antibacterial February 1990
2.Ofloxacin 200mg 20-01-2006
+ Ornidazole 500mg
For diarrhea of mixed origin
3.Ofloxacin 2mg 17-08-2009
+ Ornidazole 5mg per 5ml
infusion
For the treatment of diarrhea of mixed infection in adult patients
PATENT EXPIRY DATES OF DRUGS
Chemical Category Manufacturer/ US Patent
Ingredient- Marketer Expiration Date
Ofloxacin Antibiotic Johnson & Johson 02-09-2003
Adverse Reaction:
Nausea, vomiting, abdominal pain, diarrhoea, headache, dizzines, and insomnia, rarely seizures and hallucinations.
Leucopenia and eosinophilia.
Contra-Indications:
Hypersens to 4-quinolones.Children,pregnancy & lactation.
History of convulsive disorders.
Special precautions:
Avoid exposure to strong sunlight and UV rays. Magnesium and Aluminium antacids may reduce absorption.
Dosages/ Overdosage Etc:
Approved by FDA in 1990
Indications:
Lower respiratory infections, sexually transmitted diseases, skin and skin structure and urinary tract infections, prostatitis.
Dosage:
Chronic bronchitis- Daily dose 800mg- 400mg 12 hourly for 10 days. Pneumonia - Daily dose 800mg - 400mg 12 hourly for 10 days..
Uncomplicated gonorrhoea - Daily dose 400mg , single dose for one day. Cervititis/urethritis - daily dose 600mg- 300mg 12 hourly for 7 days. Administer infusion thro' I.V. only.
Do not give I.M.intrthecally, interperitonally or SC. Avoid rapid or bolus IV infusion. Administer slowly over a period of not less than 60 minutes..
Other Information:
For Availability/supplies
Contact -
1.Indian Drug Manufacturers Association (IDMA)
Phone- 022- 24944624/ 24974308
Fax- 022- 24950723
Email- idma@vsnl.com
Website: www.idma-assn.org
2.Bulk Drug Manufacturers Association (India)(BDMA)
Phone - 040-23703910/ 23706718
Fax- 040-23704804
Email- info@bdmai.org
Website: www.info@bdmai.org
Patient Information:
Ref - USP PDI Vol II 17th Edition (1997)
OFLOXACIN - Ophthalmic-
1.Allergies-
Tell your doctor if you have ever had any unusual or allergic reaction to
ophthalmic or systemic ofloxacin, or any other related medicines.
Also tell your healthcare care professional if you are allergic to any other
substances such as foods. preservatives or dyes.
2.Pregnancy-
Ophthalic ofloxacin has not been studied in pegnant women.
Before taking this medicine make sure that your doctor knows
that you are pregnant or if you may become pregnant
3. Breast-feeding-
Mothers who are taking this medicine and who wish to breast feed should discuss this
with their doctor.
4.Children-
Use is not recommended in infants, up to 1 year of age. In children
1 year and older, this medicine is not to cause different side effects or
problems than it does in adults.
5.Older adults-
There is no specific information comparing use of ophthalmic
ofloxacin in the elderly with use in other age groups
6. Other medicines-
Tell your doctor if you are using any other prescription or
non-prescription (Over-the counter) OTC medicine.
Pharmacology/ Pharmacokinetics:
Refer fluoroquinolones
Interaction with Food:
Rate of absorption reduced.
Pregnancy and lactation:
Refer fluoroquinolones
Manufacturer Details